Edit |   |
---|---|
Antigenic Specificity | Fodrin/Alpha Spectrin II (SPTAN1)/NEAS |
Clone | [SPTAN1/3351] |
Host Species | Mouse |
Reactive Species | human |
Isotype | IgG2b, kappa |
Format | purified |
Size | 0.02 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (With BSA & Azide at 0.2mg/ml), 0.1 mg (Without BSA & Azide at 1mg/ml) |
Concentration | n/a |
Applications | Immunohistochemistry (IHC) Paraffin |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Specificity: Spectrin, an actin binding protein that is a major component of the cytoskeletal superstructure of the erythrocyte plasma membrane, is essential in determining the properties of the membrane including its shape and deformability. Spectrins function as membrane organizers and stabilizers, composed of nonhomologous and chains, which aggregate side-to-side in an antiparallel fashion to form dimers, tetramers, and higher polymers. Spectrin I and spectrin I are present in erythrocytes, whereas spectrin II (also designated fodrin) and spectrin II (also designated fodrin) are present in other somatic cells. The spectrin tetramers in erythrocytes act as barriers to lateral diffusion, but spectrin dimers seem to lack this function. Acti |
Immunogen | Immunogen: Recombinant fragment of human SPTAN1 protein (around aa 2351-2475) (exact sequence is proprietary) |
Other Names | [Alpha-II spectrin; brain; EIEE5; Fodrin alpha chain; NEAS; Non erythrocytic spectrin alpha; non-erythroid alpha chain; SPECA; Spectrin alpha chain brain; Spectrin; alpha; non-erythrocytic 1 (alpha-fodrin); Spna2; SPTA2] |
Gene, Accession # | [SPTAN1], Gene ID: 6709, NCBI: NP_001123910.1, UniProt: Q13813 |
Catalog # | MBS4381265 |
Price | $190, $340, $340 |
Order / More Info | Fodrin/Alpha Spectrin II (SPTAN1)/NEAS Antibody from MYBIOSOURCE INC. |
Product Specific References | Wang Y et al. Critical roles of aII spectrin in brain development and epileptic encephalopathy. J Clin Invest 128:760-773 (2018). |